A Deal A Month? After Dusa, India’s Sun Bags URL’s Generics Business As Takeda Keeps Colcrys
This article was originally published in PharmAsia News
Sun Pharma continues its acquisition spree in the U.S. under new Chairman Israel Makov.
You may also be interested in...
Sun Finally Gains Control Of Taro As Founders Relent; Charts Out Aggressive Investment And Growth Plans
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.